Abstract
Except for few cases, chemotherapeutic toxicity is in general influenced by multiple genetic factors and nongenetic factors including age, sex and drug-drug interactions. The manifestations of adverse drug reactions differ between men and women. In particular, women experience greater toxicity from certain chemotherapeutic drugs than men. Sexrelated factors are likely to play an increasing role in drug development and therapeutic decision-making in the future. The sex-selective toxicity could be attributed to sex-related differences in pharmacokinetic and pharmacodynamic properties of these drugs. Systematic pharmacogenomic investigation into sex difference in chemotherapeutic toxicity potentially presents an opportunity to assess the effects of multiple genetic factors or gene networks on sex-related differences in the toxicity of anti-cancer drugs. A thorough understanding of the interactions between sex, drug and gene will provide valuable insights in assessing the susceptibility of an individual to chemotherapy-induced toxicity, predicting the sex-related effects for any anticancer drug and ultimately achieving the goal of personalized cancer therapy.
Keywords: Sex difference, pharmacogenomics, chemotherapeutic toxicity, personalized drug therapy
Current Drug Discovery Technologies
Title: Pharmacogenomics of Sex Difference in Chemotherapeutic Toxicity
Volume: 4 Issue: 1
Author(s): Jeffrey Wang and Ying Huang
Affiliation:
Keywords: Sex difference, pharmacogenomics, chemotherapeutic toxicity, personalized drug therapy
Abstract: Except for few cases, chemotherapeutic toxicity is in general influenced by multiple genetic factors and nongenetic factors including age, sex and drug-drug interactions. The manifestations of adverse drug reactions differ between men and women. In particular, women experience greater toxicity from certain chemotherapeutic drugs than men. Sexrelated factors are likely to play an increasing role in drug development and therapeutic decision-making in the future. The sex-selective toxicity could be attributed to sex-related differences in pharmacokinetic and pharmacodynamic properties of these drugs. Systematic pharmacogenomic investigation into sex difference in chemotherapeutic toxicity potentially presents an opportunity to assess the effects of multiple genetic factors or gene networks on sex-related differences in the toxicity of anti-cancer drugs. A thorough understanding of the interactions between sex, drug and gene will provide valuable insights in assessing the susceptibility of an individual to chemotherapy-induced toxicity, predicting the sex-related effects for any anticancer drug and ultimately achieving the goal of personalized cancer therapy.
Export Options
About this article
Cite this article as:
Jeffrey Wang and Ying Huang , Pharmacogenomics of Sex Difference in Chemotherapeutic Toxicity, Current Drug Discovery Technologies 2007; 4 (1) . https://dx.doi.org/10.2174/157016307781115485
DOI https://dx.doi.org/10.2174/157016307781115485 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Complex Airway in Childhood Asthma
Current Pediatric Reviews Editorial [Hot Topic: Evolving Drug Targets in DNA Base Excision Repair for Cancer Therapy (Guest Editor: Srinivasan Madhusudan)]
Current Molecular Pharmacology Palliative Radiation of Chest Tumors
Current Cancer Therapy Reviews NFκB Pathway and microRNA-9 and -21 are Involved in Sensitivity to the Pterocarpanquinone LQB-118 in Different CML Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Molecular Approaches Target to Immunotherapy for HPV-Associated Cancers
Current Cancer Drug Targets Targets for Anti-metastatic Drug Development
Current Pharmaceutical Design Angiotensin-(1-7): A Peptide Hormone with Anti-Cancer Activity
Current Medicinal Chemistry Cancer-Type Organic Anion Transporting Polypeptide 1B3: Current Knowledge of the Gene Structure, Expression Profile, Functional Implications and Future Perspectives
Current Drug Metabolism Human Copper Chaperone Atox1 Translocates to the Nucleus but does not Bind DNA In Vitro
Protein & Peptide Letters Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimer’s Disease
Current Drug Targets Retromer's Role in Endosomal Trafficking and Impaired Function in Neurodegenerative Diseases
Current Protein & Peptide Science New Fabrication and Applications of Carbohydrate Arrays
Current Medicinal Chemistry Using Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy
Current Drug Discovery Technologies Editorial (Thematic Issue: Biosafety of Viral Vectors Commonly Used in Gene Therapy and Vaccination)
Current Gene Therapy In Vitro Models of Human T Cell Development: Dishing Out Progenitor T Cells
Current Immunology Reviews (Discontinued) Biomedical Applications of Gold Nanoparticles
Current Topics in Medicinal Chemistry Cellular Senescence in Ageing, Age-Related Disease and Longevity
Current Vascular Pharmacology Protein and Peptide Biopharmaceuticals: An Overview
Protein & Peptide Letters A Dual Role of Cyclin E in Cell Proliferation and Apotosis May Provide a Target for Cancer Therapy
Current Cancer Drug Targets Enhanced Gene Delivery and/or Efficacy by Functional Peptide and Protein
Current Topics in Medicinal Chemistry